Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is May 15, 2025, covering a share repurchase executed on May 14, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
- Shares Purchased (May 14, 2025): 591,951 ordinary shares.
- Price Range: Lowest price paid was 1,357.50 GBp; highest price paid was 1,384.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,368.22 GBp.
- Cumulative Buyback (since Feb 24, 2025): 42,045,790 ordinary shares.
- Treasury Shares Held: 211,116,093 ordinary shares.
- Shares in Issue (excluding Treasury): 4,104,140,295 ordinary shares.
- Total Voting Rights: 4,104,140,295.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity, as it is a disclosure of a specific share transaction rather than a financial results report.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares following the May 14 repurchase. The total number of voting rights remains consistent with the number of shares in issue excluding treasury shares. No other material changes to the company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new guidance or management commentary regarding future financial performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results. The purchased shares are to be held as Treasury shares.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on February 24, 2025.
- Confirm the impact of the 211,116,093 treasury shares on earnings per share (EPS) calculations.
- Review the "Risk Factors" section of the 2024 Form 20-F referenced in the cautionary statement.
- Check subsequent filings for updates on the cumulative buyback volume and remaining programme duration.